Epiruba 50 mg Injection 1's

Epiruba 50 mg Injection 1's is an anti-cancer medicine that is used in conjunction with other drugs to treat breast cancer in people who have had tumor removal surgery. Epiruba 50 mg Injection 1's is used as adjuvant chemotherapy in women with axillary lymph nodes with involvement resection of breast cancer (abnormal growth in the cells of the breast).

Epiruba 50 mg Injection 1's contains Epirubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, thereby destroying the DNA and RNA synthesis.

Epiruba 50 mg Injection 1's may cause certain side effects such as nausea, headache, abdominal pain, loss of appetite, vomiting, dizziness, mouth sores, tiredness, back pain, diarrhoea, and pain at the site of injection. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. A trained healthcare doctor will administer Epiruba 50 mg Injection 1's. So, do not self-administer. Your doctor will decide the dose of the medicine based on your health condition.

Epiruba 50 mg Injection 1's should be avoided if you are allergic to it. It is contraindicated in patients having a recent history of myocardial infarction (MI) or heart attack, patients with baseline neutrophil count < 1500 cells/mm3, severe arrhythmias, previous treatment with anthracyclines, and severe hepatic dysfunction. Hence avoid using this medicine under such conditions. Inform your doctor if you have any cardiovascular conditions, liver/kidney disease, or taking any medicines such as cardiotoxic drugs (eg, Thalidomide, doxorubicin, Abiraterone, tamoxifen, letrozole), and cimetidine, as it can cause serious adverse effects. Epiruba 50 mg Injection 1's is known to cause embryo-fetal toxicity. Hence it is contraindicated in pregnant or breastfeeding women. Epiruba 50 mg Injection 1's is not recommended for children as it is known to cause anthracycline-induced acute manifestations of cardiotoxicity and chronic CHF.

Epiruba 50 mg Injection 1's contains Epirubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, thereby destroying the DNA and RNA synthesis. It is used as adjuvant chemotherapy in women with axillary lymph nodes with involvement resection of breast cancer.

• Nausea
• Abdominal pain
• Vomiting
• Dizziness
• Back pain
• Pain at the site of injection
• Red discoloration of urine
• Loss of appetite
• Mouth sores
• Tiredness
• Weight gain
• Pale skin

Epiruba 50 mg Injection 1's should be avoided if you are allergic to it. It is contraindicated in patients having a recent history of myocardial infarction (MI) or heart attack, patients with baseline neutrophil count < 1500 cells/mm3, severe arrhythmias, previous treatment with anthracyclines and severe hepatic dysfunction. Hence avoid using this medicine under such conditions. Inform your doctor if you have any cardiovascular conditions, liver/kidney disease, or taking any medicines such as cardiotoxic drugs (e.g., Thalidomide, doxorubicin, Abiraterone, tamoxifen, letrozole), and cimetidine, as it can cause serious adverse effects. Epiruba 50 mg Injection 1's is known to cause embryo-fetal toxicity. Hence it is contraindicated in pregnant or breastfeeding women. Epiruba 50 mg Injection 1's is not recommended for children as it is known to cause anthracycline-induced acute manifestations of cardiotoxicity and chronic CHF. Do not stop receiving Epiruba 50 mg Injection 1's without a doctor’s advice, as it can cause serious health conditions. Epiruba 50 mg Injection 1's is known to cause severe life-threatening haematological reactions, tissue necrosis, cardiomyopathy, secondary acute myelogenous leukaemia, and severe myelosuppression in some patients. Hence careful monitoring of the patient is needed while receiving the medicine.

• THALIDOMIDE
• DOXORUBICIN
• ABIRATERONE
• TAMOXIFEN
• LETROZOLE
• PACLITAXEL
• DOCETAXEL
• CIMETIDINE
• CILNIDIPINE
• NIFEDIPINE

• Avoid having intercourse while on treatment with Epiruba 50 mg Injection 1's.
• Regular monitoring of complete blood count  (CBC) and liver function (LFT) is important while receiving Epiruba 50 mg Injection 1's.

• Try to eat more healthy fats, fruits, vegetables and whole-grain foods to give you more energy. 
• Stay hydrated by drinking plenty of water, as dehydration is often seen in cancers.
• Taking a stroll in the garden or spending 30 minutes of your time doing some light physical activity can be very useful. However, do not over-exert yourself if you feel too tired. 
• Avoid smoking and alcohol consumption.
• Doing meditation and yoga for some time is very effective in helping cancer patients maintain a healthy attitude and body.